Foamix Pharmaceuticals Ltd. Contracts & Agreements
31 Contracts & Agreements
- Business Finance (8 contracts)
- Business Operations (7)
- Human Resources (7)
- Mergers & Acquisitions (2)
- Real Estate (4)
- Uncategorized (3)
- Description of Securities Registered Under Section 12 of the Exchange Act (Filed With SEC on March 12, 2020)
- Contract Manufacturing and Supply Agreement, dated October 21, 2019, by and between Foamix Pharmaceuticals Ltd. and ASM Aerosol-Service AG (Filed With SEC on March 12, 2020)
- Amendment No. 1 to the Agreement and Plan of Merger, dated as of December 4, 2019, by and among Foamix Pharmaceuticals Ltd., Menlo Therapeutics Inc. and Giants Merger Subsidiary... (Filed With SEC on December 4, 2019)
- U.S. Security Agreement among Foamix Pharmaceuticals Inc., Foamix Pharmaceuticals Ltd. and Perceptive Credit Holdings II, LP for the benefit of Perceptive Credit Holdings II, LP,... (Filed With SEC on November 12, 2019)
- Warrant Certificate issued by Foamix Pharmaceuticals Ltd. for the benefit of OrbiMed Royalty & Credit Opportunities III, LP (Filed With SEC on November 12, 2019)
- Warrant Certificate issued by Foamix Pharmaceuticals Ltd. for the benefit of Perceptive Credit Holdings II, LP (Filed With SEC on November 12, 2019)
- Form of Menlo Voting Agreement (Filed With SEC on November 12, 2019)
- FORM OF FOAMIX VOTING AGREEMENT (Filed With SEC on November 12, 2019)
- Form of Foamix Voting Agreement (Filed With SEC on November 12, 2019)
- Credit Agreement and Guaranty among Foamix Pharmaceuticals Inc., Foamix Pharmaceuticals Ltd., Perceptive Credit Holdings II, LP, OrbiMed Royalty & Credit Opportunities III, LP and... (Filed With SEC on November 12, 2019)
- Agreement and Plan of Merger, dated as of November 10, 2019, by and among Foamix Pharmaceuticals Ltd., Menlo Therapeutics Inc. and Giants Merger Subsidiary Ltd (Filed With SEC on November 12, 2019)
- Controlled Equity Offering Sales AgreementSM, dated August 19, 2019, by and between Foamix Pharmaceuticals Ltd. and Cantor Fitzgerald & Co (Filed With SEC on August 19, 2019)
- Share Purchase Agreement, dated July 29, 2019, by and among the Company and Perceptive Life Sciences Master Fund, Ltd (Filed With SEC on July 30, 2019)
- Amendment to Lease Agreement, dated March 13, 2019, between Foamix Pharmaceuticals Inc. and S/K 520 Associates (Filed With SEC on May 7, 2019)
- Amendment to offer letter agreement between Foamix Pharmaceuticals Inc. and Mutya Harsch (Filed With SEC on May 7, 2019)
- Form of amendment to employment agreement between Foamix Pharmaceuticals Ltd. and Ilan Hadar (Filed With SEC on May 7, 2019)
- Form of Share Option Grant Notice and Option Agreement under the Foamix Pharmaceuticals Ltd. 2019 Equity Incentive Plan (Filed With SEC on May 7, 2019)
- Form of Restricted Share Unit Grant Notice and Restricted Share Unit Award Agreement under the Foamix Pharmaceuticals Ltd. 2019 Equity Incentive Plan (Filed With SEC on May 7, 2019)
- Foamix Pharmaceuticals Ltd. 2019 Equity Incentive Plan (Filed With SEC on April 11, 2019)
- Foamix Pharmaceuticals Ltd. 2019 Employee Share Purchase Plan (Filed With SEC on April 11, 2019)
- Summary of Lease Agreement, dated as of May 7, 2008, as amended on April 18, 2016, by and between the Registrant and Gav Yam Real Estate Ltd (Filed With SEC on February 28, 2019)
- Foamix Pharmaceuticals Ltd. Amended Compensation Policy for Officers and Directors (Filed With SEC on February 28, 2019)
- Employment Agreement by and between Foamix Pharmaceuticals Inc. and David Domzalski, dated November 27, 2017 (Filed With SEC on February 28, 2019)
- Employment Agreement by and between Foamix Pharmaceuticals Ltd. and Ilan Hadar, dated September 13, 2017 (Filed With SEC on February 28, 2019)
- Offer Letter Agreement by and between Foamix Pharmaceuticals Inc. and Mutya Harsch, dated November 17, 2018 (Filed With SEC on February 28, 2019)
- Lease Agreement, dated as of October 25, 2017, between Foamix Pharmaceuticals Inc. and S/K 520 Associates (Filed With SEC on February 28, 2019)
- Underwriting Agreement, dated September 13, 2018, among Foamix Pharmaceuticals Ltd., and Merrill Lynch, Pierce, Fenner & Smith, Cowen and Company, LLC and Barclays Capital Inc.,... (Filed With SEC on September 18, 2018)
- Securities Purchase Agreement dated as of April 13, 2018, by and between Foamix Pharmaceuticals Ltd. and OrbiMed Partners Master Fund Limited (Filed With SEC on April 16, 2018)
- Termination Agreement of Dr. Dov Tamarkin, effective as of July 1, 2017 (Filed With SEC on February 27, 2018)
- Termination Agreement of Mr. Meir Eini, effective as of July 1, 2017 (Filed With SEC on February 27, 2018)
- Lease Agreement, dated as of October 25, 2017, between Foamix Pharmaceuticals Inc. and S/K 520 Associates (Filed With SEC on February 27, 2018)
